Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US

被引:15
|
作者
Shah, Drishti [1 ]
Allen, Lindsay [2 ]
Zheng, Wanhong [3 ]
Madhavan, Suresh S. [1 ,4 ]
Wei, Wenhui [1 ,5 ]
LeMasters, Traci J. [1 ]
Sambamoorthi, Usha [1 ,4 ]
机构
[1] West Virginia Univ, Sch Pharm, Dept Pharmaceut Syst & Policy, POB 9510, Morgantown, WV 26506 USA
[2] West Virginia Univ, Sch Publ Hlth, Hlth Policy Management & Leadership Dept, Morgantown, WV 26506 USA
[3] West Virginia Univ, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA
[4] Univ North Texas, Hlth Sci Ctr, Coll Pharm, Dept Pharmacotherapy, Ft Worth, TX USA
[5] Regeneron Pharmaceut, Tarrytown, NY USA
关键词
HEALTH-CARE EXPENDITURES; ANTIDEPRESSANT TREATMENT; TREATMENT RESPONSE; OUTCOMES; IMPACT; COSTS; POLYPHARMACY; PREVALENCE; DISABILITY; RISK;
D O I
10.1007/s40273-021-01029-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective Major depressive disorder (MDD) and chronic non-cancer pain conditions (CNPC) often co-occur and exacerbate one another. Treatment-resistant depression (TRD) in adults with CNPC can amplify the economic burden. This study examined the impact of TRD on direct total and MDD-related healthcare resource utilization (HRU) and costs among commercially insured patients with CNPC and MDD in the US. Methods The retrospective longitudinal cohort study employed a claims-based algorithm to identify adults with TRD from a US claims database (January 2007 to June 2017). Costs (2018 US$) and HRU were compared between patients with and without TRD over a 12-month period after TRD/non-TRD index date. Counterfactual recycled predictions from generalized linear models were used to examine associations between TRD and annual HRU and costs. Post-regression linear decomposition identified differences in patient-level factors between TRD and non-TRD groups that contributed to the excess economic burden of TRD. Results Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD. TRD patients had significantly higher HRU, translating into higher average total costs (US$21,015(TRD) vs US$14,712(No TRD)) and MDD-related costs (US$1201(TRD) vs US$471(No TRD)) compared with non-TRD patients (all p < 0.001). Prescription drug costs accounted for 37.6% and inpatient services for 30.7% of the excess total healthcare costs among TRD patients. TRD patients had a significantly higher number of inpatient (incidence rate ratio [IRR] 1.30, 95% CI 1.14-1.47) and emergency room visits (IRR 1.21, 95% CI 1.10-1.34) than non-TRD patients. Overall, 46% of the excess total costs were explained by differences in patient-level characteristics such as polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD and non-TRD groups. Conclusion TRD poses a substantial direct economic burden for adults with CNPC and MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for several modifiable risk factors.
引用
收藏
页码:639 / 651
页数:13
相关论文
共 50 条
  • [41] Trends in opioid and non-opioid treatment for chronic non-cancer pain and cancer pain among privately insured adults in the United States, 2012-2019
    Bandara, Sachini
    Bicket, Mark C. C.
    McGinty, Emma E. E.
    PLOS ONE, 2022, 17 (08):
  • [42] EXCESS OUT-OF-POCKET EXPENDITURES AND BURDEN OF PRESCRIPTION OPIOID USE AMONG OLDER CANCER SURVIVORS WITH NON-CANCER CHRONIC PAIN CONDITIONS (NCPC)
    Safarudin, R.
    LeMasters, T.
    Kamran, A.
    Higa, G.
    Sambamoorthi, U.
    VALUE IN HEALTH, 2023, 26 (06) : S107 - S107
  • [43] Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization
    McIntyre, Roger S.
    Millson, Brad
    Power, G. Sarah
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 277 : 30 - 38
  • [44] US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
    Pilon, Dominic
    Szukis, Holly
    Joshi, Kruti
    Singer, David
    Sheehan, John J.
    Wu, Jennifer W.
    Lefebvre, Patrick
    Greenberg, Paul
    PHARMACOECONOMICS-OPEN, 2020, 4 (01) : 119 - 131
  • [45] US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
    Dominic Pilon
    Holly Szukis
    Kruti Joshi
    David Singer
    John J. Sheehan
    Jennifer W. Wu
    Patrick Lefebvre
    Paul Greenberg
    PharmacoEconomics - Open, 2020, 4 : 119 - 131
  • [46] Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
    Young, Allan H.
    Abdelghani, Mohamed
    Juruena, Mario F.
    Nikolova, Viktoriya L.
    Nilforooshan, Ramin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 433 - 441
  • [47] Major depressive disorder, suicidal behaviour, bipolar disorder, and generalised anxiety disorder among emerging adults with and without chronic health conditions
    Ferro, M. A.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2016, 25 (05) : 462 - 474
  • [48] Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study
    Pappa, Sofia
    Shah, Moulesh
    Young, Sophie
    Anwar, Tazneem
    Ming, Timothy
    BJPSYCH OPEN, 2024, 10 (01):
  • [49] Metabolic features of adolescent major depressive disorder: A comparative study between treatment-resistant depression and first-episode drug-naive depression
    Gan, Xieyu
    Li, Xuemei
    Cai, Yuping
    Yin, Bangmin
    Pan, Qiyuan
    Teng, Teng
    He, Yuqian
    Tang, Han
    Wang, Ting
    Li, Jie
    Zhu, Zhengjiang
    Zhou, Xinyu
    Li, Jinfang
    PSYCHONEUROENDOCRINOLOGY, 2024, 167
  • [50] Psychometric evaluation of the Depression Anxiety Stress Scale 8 among women with chronic non-cancer pelvic pain
    Amira Mohammed Ali
    Amin Omar Hendawy
    Rasmieh Al-Amer
    Ghada Shahrour
    Esraa M. Ali
    Abdulmajeed A. Alkhamees
    Nashwa Ibrahim
    Sahar Mansour Taha Lamadah
    Afaf Hassan Ahmed
    Scientific Reports, 12